Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC
The combination of osimertinib (Tagrisso) and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to the final analysis of the primary end point of the phase 3 FLAURA2 … [Read more…]